2,489 件 ・ 関連度順
概要と使いどころ
Audit LLM token cost estimates against actual API usage. Activate on 'cost verification', 'token estimate accuracy', 'API cost audit', 'estimation variance'. NOT for pricing lookups, budget planning, or cost optimization strategies.
日本語の概要は準備中です。原文の説明を表示しています。
Validates agent outputs against schemas and quality criteria, scores confidence, detects hallucinations, monitors convergence, decides when to iterate, and synthesizes actionable feedback. Use when checking if a node's output is acceptable, scoring confidence, detecting fabricated content, deciding whether to re-execute, or generating improvement feedback. Activate on "validate output", "check quality", "confidence score", "hallucination check", "should we iterate", "improvement feedback". NOT for executing DAGs (use dag-runtime), planning DAGs (use dag-planner), or matching skills (use dag-skills-matcher).
日本語の概要は準備中です。原文の説明を表示しています。
Executes DAG workflows with parallel wave processing, agent spawning, context isolation, permission enforcement, and full execution tracing. Use when running a planned DAG, managing concurrent agent execution, enforcing isolation boundaries, or tracing execution for debugging. Activate on "execute DAG", "run workflow", "spawn agents", "parallel execution", "execution trace", "agent isolation". NOT for planning DAGs (use dag-planner), validating outputs (use dag-quality), or matching skills (use dag-skills-matcher).
日本語の概要は準備中です。原文の説明を表示しています。
Operations, debugging, and optimization for DAG workflows. Performs root cause analysis on failures, profiles execution performance, aggregates results from parallel branches, bridges context between nodes, and learns patterns from execution history. Activate on "DAG failed", "why did it fail", "root cause", "performance profile", "aggregate results", "merge branches", "execution patterns", "optimize DAG". NOT for planning DAGs (use dag-planner), executing DAGs (use dag-runtime), or validating outputs (use dag-quality).
日本語の概要は準備中です。原文の説明を表示しています。
The intelligence layer of WinDAGs. Decomposes natural language tasks into Hierarchical Task DAGs (HTDAGs), matches subtasks to skills, executes waves in parallel, and dynamically expands nodes when complexity exceeds executor capability. Use for 'orchestrate', 'execute DAG', 'parallel agents', 'decompose task', 'coordinate skills'. NOT for single-skill tasks or simple linear workflows.
日本語の概要は準備中です。原文の説明を表示しています。
Modifies DAG structure during execution in response to failures, new requirements, or runtime discoveries. Supports node insertion, removal, and dependency rewiring. Activate on 'replan dag', 'modify workflow', 'add node', 'remove node', 'dynamic modification'. NOT for initial DAG building (use dag-graph-builder) or scheduling (use dag-task-scheduler).
日本語の概要は準備中です。原文の説明を表示しています。
Choose, compare, and decompose work into the right coordination topology: dag, workflow, manager-driven team, swarm, blackboard, team-builder, or recurring loop. Use when the coordination shape is unclear, when you need topology-native breakdown instructions instead of a generic DAG, or when planning topology and runtime topology may differ. NOT for actual execution, node-level skill matching, or framework/tool installation.
日本語の概要は準備中です。原文の説明を表示しています。
Handle mental health crisis situations in AI coaching safely. Use when implementing crisis detection, safety protocols, emergency escalation, or suicide prevention features. Activates for crisis keywords, safety planning, hotline integration, and risk assessment.
日本語の概要は準備中です。原文の説明を表示しています。
license: Apache-2.0 NOT for unrelated tasks outside this domain.
日本語の概要は準備中です。原文の説明を表示しています。
Choose multi-agent architectures using environment-first analysis, coordination pressure, commitment tuning, and knowledge levels. Use for autonomy design, protocol choice, and coordination failures. NOT for single-agent planning, centralized schedulers, or prompt-only swarms.
日本語の概要は準備中です。原文の説明を表示しています。
Identifies differential m6A methylation between conditions from MeRIP-seq paired IP/input data using exomePeak2 (GC-bias-aware differential via its bam_ip/bam_input control + bam_treated_ip/bam_treated_input treatment arms), QNB beta-binomial, MeTDiff HMM, and RADAR, plus the paired-symmetric edgeR/DESeq2-on-peak-counts route when batch/lot covariates need fixed-effect handling that exomePeak2's API does not accept. Covers paired vs unpaired vs interaction designs, batch confounding and per-lot meta-analysis, the stoichiometry-vs-expression-vs-IP-efficiency confound, and effect-size filtering against under-powered N=2 designs. Use when comparing m6A across two or more conditions, choosing between exomePeak2/QNB/RADAR/MeTDiff for a design, handling batch confounding when exomePeak2's API is too rigid, distinguishing real hyper/hypo-methylation from expression shifts, applying effect-size thresholds, or planning orthogonal stoichiometry validation (GLORI/SAC-seq/m6Anet mod_ratio).
日本語の概要は準備中です。原文の説明を表示しています。
Calculates statistical power for high-dimensional genomics experiments (bulk RNA-seq, scRNA-seq, ATAC-seq, ChIP-seq, methylation, proteomics) under negative-binomial count models using RNASeqPower, PROPER, and simulation via powsimR, distinguishing per-gene from marginal (transcriptome-wide) power, the role of mean expression and dispersion, and the sequencing-depth-versus-replicate tradeoff. Covers simulation as the honest default for overdispersed counts, FDR-aware average power versus single-test power, observed/post-hoc power as an anti-pattern, and the winner's-curse / Type-S / Type-M consequences of underpowering. Use when planning replicate number for a sequencing experiment, deciding whether to add depth or samples, choosing closed-form versus simulation power, estimating power from pilot dispersions, or justifying replication in a grant. For clinical-trial power see clinical-biostatistics/power-and-sample-size; for the inverse sample-size question see experimental-design/sample-size.
日本語の概要は準備中です。原文の説明を表示しています。
Structures biological experiments so inference is valid by construction, covering Fisher's principles (randomization, replication, local control), the experimental-vs-observational unit distinction and pseudoreplication (Hurlbert 1984; Lazic 2018), randomization mechanics (complete, restricted, stratified, rerandomization, run-order), blocking layouts (randomized complete block, Latin square, incomplete block), factorial designs and interactions, and the split-plot/nested error strata hidden inside multi-batch genomics. Use when deciding the experimental unit and what counts as a replicate, planning randomization and run order, choosing a blocked/factorial/split-plot/nested layout, avoiding pseudoreplication in cell-culture or animal studies, or specifying the random-effects structure of the analysis model. For assigning samples to sequencing batches/lanes/plates and batch-effect correction see experimental-design/batch-design; for regulated clinical-trial randomization see clinical-biostatistics.
日本語の概要は準備中です。原文の説明を表示しています。
Estimates the minimum biological replicates (or cells/events) for a target power at a target FDR in genomics experiments using ssizeRNA, PROPER, powsimR for scRNA-seq, and pilot-data dispersion estimation from DESeq2/edgeR. Covers the biological-versus-technical replication distinction (technical replicates do not add degrees of freedom for biological inference), replicate-number-versus-sequencing-depth budgeting, scRNA-seq sample-versus-cell allocation under a pseudobulk model, and the critique that "n=3" is a publication convention rather than a power calculation. Use when budgeting a sequencing experiment, writing the sample-size justification in a grant, estimating replicates from pilot data, allocating a fixed budget between samples and depth, or planning scRNA-seq cohort size. For clinical-trial sample size see clinical-biostatistics/power-and-sample-size; for the power-given-n direction see experimental-design/power-analysis.
日本語の概要は準備中です。原文の説明を表示しています。
Simulate transcription factor perturbation effects on cell state in silico with CellOracle and Dynamo, and predict transcriptional responses to genetic perturbations with GEARS, scGen, and CPA. Covers the direction-not-magnitude principle, local-linear validity, the GRN/velocity error it inherits, baseline discipline (mean and additive baselines), and the validation gap. Use when predicting TF knockout or overexpression effects, ranking driver TFs for fate transitions, or planning perturbation experiments. For GRN construction see multiomics-grn; for experimental Perturb-seq see single-cell/perturb-seq.
日本語の概要は準備中です。原文の説明を表示しています。
Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.
日本語の概要は準備中です。原文の説明を表示しています。
Guidance for choosing the right protein binder design tool. Use this skill when: (1) Deciding between BoltzGen, BindCraft, or RFdiffusion, (2) Planning a binder design campaign, (3) Understanding trade-offs between different approaches, (4) Selecting tools for specific target types. For specific tool parameters, use the individual tool skills (boltzgen, bindcraft, rfdiffusion, etc.).
日本語の概要は準備中です。原文の説明を表示しています。
Guidance for SPR and BLI binding characterization experiments. Use when: (1) Planning binding kinetics experiments, (2) Troubleshooting poor/no binding signal, (3) Interpreting kinetic data artifacts, (4) Choosing between SPR vs BLI platforms.
日本語の概要は準備中です。原文の説明を表示しています。
Migrate from AngularJS to Angular using hybrid mode, incremental component rewriting, and dependency injection updates. Use when upgrading AngularJS applications, planning framework migrations, or modernizing legacy Angular code.
日本語の概要は準備中です。原文の説明を表示しています。
Assesses whether hysterectomy and oophorectomy are medically necessary as part of gender-affirming surgery for transgender patients. Triggered when a patient is planning gender-affirming surgery and clinicians need to determine if total hysterectomy and oophorectomy should be included.
日本語の概要は準備中です。原文の説明を表示しています。
Recommends postpartum endocrine care (diabetes management) in addition to usual obstetric care for individuals with preexisting diabetes (including those with pregnancy loss or termination). Triggered by postpartum care planning for patients with diabetes after delivery.
日本語の概要は準備中です。原文の説明を表示しています。
Recommends contraception when pregnancy is not desired for individuals with diabetes who could become pregnant. Triggered by discussions about pregnancy planning, contraception needs, or when pregnancy is not desired.
日本語の概要は準備中です。原文の説明を表示しています。
This skill screens for pregnancy intention in individuals with preexisting diabetes at every reproductive, diabetes, primary care, and urgent care/ER visit when clinically appropriate. Trigger phrases include reproductive planning, preconception care, or pregnancy intention discussion.
日本語の概要は準備中です。原文の説明を表示しています。
Suggests initiating inpatient continuous glucose monitoring (CGM) for select hospitalized patients at high risk for hypoglycemia, combined with periodic point-of-care glucose checks for accuracy. Triggers include planning glucose monitoring for inpatients with prior severe hypoglycemia, renal or hepatic dysfunction, or age 65 years or older.
日本語の概要は準備中です。原文の説明を表示しています。